SCAVENGER RECEPTOR B1 (CLA-1) TARGETING FOR THE TREATMENT OF INFECTION, SEPSIS AND INFLAMMATION

摘要

This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-BI, which is also referred to as CLA-1 (SR-BI/CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SRB I/CLA-1 ligands contributing to the pathogenesis of disease include LPS, LTA, viral envelope proteins, beta-amyloid, serum Amyloid A and/or heat shock proteins.